← Back to headlines
Viking Therapeutics Plans VK2735 Phase III Start in Q4
Viking Therapeutics anticipates initiating Phase III trials for its oral drug VK2735 in the fourth quarter, with the VANQUISH study targeting a 78-week dosing regimen.
30 Jul, 02:56 — 30 Jul, 02:56
Sources
Showing 1 of 1 sources
